Related Experiment Video
Updated: Aug 27, 2025

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Small molecule SJ572946 activates BAK to initiate apoptosis
Giridhar Sekar1,2, Geetika Singh1,2,3, Xingping Qin4,5,6
1Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Abstract:
Poration of the outer mitochondrial membrane by the effector BCL-2 proteins BAK and BAX initiates apoptosis. BH3-only initiators BID and BIM trigger conformational changes in BAK and BAX transforming them from globular dormant proteins to oligomers of the apoptotic pores. Small molecules that can directly activate effectors are being sought for applications in cancer treatment. Here, we describe the small molecule SJ572946, discovered in a fragment-based screen that binds to the activation groove of BAK and selectively triggers BAK activation over that of BAX in liposome and mitochondrial permeabilization assays. SJ572946 independently kills BAK-expressing BCL2allKO HCT116 cells revealing on target cellular activity. In combination with apoptotic inducers and BH3 mimetics, SJ572946 kills experimental cancer cell lines. SJ572946 also cooperates with the endogenous BAK activator BID in activating a misfolded BAK mutant substantially impaired in activation. SJ572946 is a proof-of-concept tool for probing BAK-mediated apoptosis in preclinical cancer research.
Insights
Researchers discovered SJ572946, a small molecule that directly activates BAK, a key protein in apoptosis. This molecule shows potential for cancer treatment by selectively inducing cell death in cancer cells.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Apoptosis, or programmed cell death, is initiated by the outer mitochondrial membrane permeabilization.
- This process is mediated by BCL-2 family proteins, specifically the effector proteins BAK and BAX.
- BH3-only proteins like BID and BIM activate BAK and BAX, leading to the formation of apoptotic pores.
Purpose of the Study:
- To identify and characterize small molecules that can directly activate effector BCL-2 proteins for cancer therapy.
- To investigate the mechanism of action and cellular activity of a novel small molecule, SJ572946.
Main Methods:
- Fragment-based screening to discover SJ572946.
- Liposome and mitochondrial permeabilization assays to assess protein activation.
- Cell-based assays using BAK-expressing cancer cells (BCL2allKO HCT116) and experimental cancer cell lines.
Main Results:
- SJ572946 selectively binds to and activates BAK, but not BAX.
- The molecule induces BAK-dependent cell death in cancer cells.
- SJ572946 enhances the efficacy of existing apoptosis inducers and BH3 mimetics.
- It also cooperates with BID to activate a resistant BAK mutant.
Conclusions:
- SJ572946 is a novel small molecule activator of BAK.
- It demonstrates on-target cellular activity and potential for combination cancer therapy.
- This molecule serves as a valuable tool for studying BAK-mediated apoptosis in preclinical research.
More Related Videos
08:47Lighting Up the Pathways to Caspase Activation Using Bimolecular Fluorescence Complementation
Published on: March 5, 2018
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
Related Concept Videos
The Intrinsic Apoptotic Pathway
The JAK-STAT Signaling Pathway
The Extrinsic Apoptotic Pathway
Caspases
Apoptosis
MAPK Signaling Cascades